ArticleEuropean journal of pediatrics2025
Serum uric acid level as a marker associated with microalbuminuria in pediatric patients with type 1 diabetes mellitus.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes mellitus (T1DM) is a common chronic disease in children and adolescents. Diabetic kidney disease (DKD) is one of its most serious microvascular complications. Serum uric acid (SUA) has been associated with an increased risk of DKD. The aim of this study was to evaluate the association between SUA levels and the presence of microalbuminuria, an important and early marker of DKD, in pediatric patients with T1DM. This retrospective study included 138 pediatric patients who were followed up with a diagnosis of T1DM for at least 1 year. Patients were divided into two groups, normoalbuminuric and microalbuminuric, according to the urine albumin/creatinine ratio (uACR) and were also divided into two groups according to SUA levels, < 3.98 mg/dL and ≥ 3.98 mg/ dL. The mean SUA level of 138 patients with T1DM was 3.85 ± 1.0 mg/dL. The mean SUA level was significantly higher in the microalbuminuria group compared to the normoalbuminuria group. ROC curve analysis revealed that mean SUA level at a cut-off of 3.98 mg/dL was associated with the presence of albuminuria, with an AUC of 0.66 (p: 0.008, 95% CI [0.56-0.76]) yielding 63% sensitivity and 65% specificity. The rate of microalbuminuria was found to be 3.06 times significantly higher among patients with SUA level of ≥ 3.98 mg/dL (p = 0.008, OR 3.06, 95% CI [1.31-7.13]).
conclusionsThe mean SUA level was significantly higher in the microalbuminuria group and the rate of microalbuminuria is higher in patients with T1DM when SUA was ≥ 3.98 mg/dL. These findings indicate a potential link between elevated SUA levels and early renal involvement in pediatric T1DM, though the proposed cut-off should be interpreted with caution. WHAT IS KNOWN: • Serum uric acid levels have been associated with an increased risk of developing DKD and development of albuminuria has been linked to higher SUA levels in patients with diabetes. WHAT IS NEW: • The mean SUA level demonstrated a moderate discriminative ability for microalbuminuria, with an AUC of 0.66 (p = 0.008, 95% CI [0.56-0.76]), providing 63% sensitivity and 65% specificity at a cut-off value of 3.98 mg/dL. • The rate of microalbuminuria is 3.06 times higher in pediatric patients with T1DM when SUA is ≥ 3.98 mg/dL. • Considering the ongoing debate regarding the definition of elevated SUA levels even in healthy individuals, the proposed cut-off may serve as a preliminary reference for future studies exploring risk assessment and follow-up in this population.
Indexed as
Identifiers
41329208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.